Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2016-10-10 Regulatory Filings
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
ATL1103 Higher Dose Study 2 pages 50.4KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about the completion and results of a clinical study (ATL1103 Higher Dose Study) conducted by Antisense Therapeutics Limited. It discusses the study design, patient dosing, efficacy endpoints, safety outcomes, and future implications for drug development. There are no financial statements, regulatory certifications, or formal financial reporting elements present. The content focuses on clinical trial results and company progress updates rather than financial performance or regulatory compliance filings. This type of document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress and results that does not fit into other specific financial or corporate filing categories.
2016-10-10 English
Notice of Annual General Meeting/Proxy Form/Annual Report 91 pages 3.5MB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and includes details about the meeting date, location, and agenda items such as the consideration of the Annual Financial Report, resolutions for director elections, remuneration report adoption, capital reduction, constitution amendments, and new option issue. It also mentions proxy forms and explanatory notes accompanying the notice. The document is a formal notice sent to shareholders to inform them about the AGM and the matters to be voted on. It does not contain the actual Annual Report or financial statements but refers to them as attached or included in the meeting materials. Therefore, this document is the official notice of the AGM, including proxy and explanatory notes, rather than the report itself or voting results. Hence, the appropriate classification is AGM Information (AGM-R).
2016-10-10 English
Less Than Marketable Parcel Share Sale Program 7 pages 77.7KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 11 October 2016 from Antisense Therapeutics Limited regarding a 'Less Than Marketable Parcel Share Sale Program'. It details the program's purpose, eligibility criteria, key dates, and instructions for shareholders to either sell or retain their small shareholdings. The document includes a Notice of Divestiture and a Share Retention Form to be returned by shareholders. It is not a financial report, earnings release, or management discussion but rather a shareholder communication about a capital management initiative involving share sales of small parcels. The document is lengthy (15,000 characters) and contains detailed program information, but it is not a report of financial results or a regulatory filing about a report publication. It is an announcement about a capital structure change (sale of shares held in small parcels) and the related shareholder process. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-10-10 English
Capital Management Initiatives - Update 2 pages 340.4KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Capital Management Initiatives - Update' and discusses several capital-related actions: a facility for the sale of less than marketable parcels, cancellation of 8.5% of issued capital shares held by Strongbridge, and issuance of bonus and new options. It references shareholder approval at the upcoming AGM but does not contain financial statements or detailed financial results. The content focuses on capital structure changes, share cancellations, and option issues, which are typical of capital or financing updates. The document length is 6647 characters, which is substantive and not a mere announcement of a report. There is no indication that this is an earnings release, annual report, or regulatory filing. Therefore, the document best fits the category of Capital/Financing Update (CAP).
2016-10-10 English
Change of Director's Interest Notice (GP) 2 pages 22.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares acquired and disposed, dates of changes, and nature of the transactions. The document is a formal notification of insider share transactions by a company director. It does not contain financial statements, earnings data, or management discussion. The content matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3809 characters, consistent with a notice rather than a full report. Therefore, the correct classification is DIRS.
2016-09-06 English
Company Update 1 page 21.7KB
Regulatory Filings Classification · 95% confidence The document is a company update from Antisense Therapeutics Limited dated 26 August 2016. It discusses the Board's recent meeting to assess progress on partnering and funding initiatives, strategic options, and upcoming business development activities including attendance at a partnering conference. There are no financial statements, detailed financial data, or regulatory form references. The document is short (2411 characters) and serves as a general business update rather than a formal report or filing. It does not announce voting results, management changes, or legal proceedings. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best as a general regulatory announcement or company update that does not fit other specific categories, thus falling under Regulatory Filings (RNS).
2016-08-25 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.